Apparatus and method for the assessment of concentration profiling and permeability rates
An apparatus for the combined assessment of dissolution and permeability relies on a receiver chamber that is contained within a donor chamber. A membrane is provided between the two chambers. Measurements can be taken to determine solute amounts of a drug introduced in the donor chamber and amounts of permeated solute in the receiver chamber. Also described are techniques for the assessment of a dissolution rate and total amount of dissolved compound, together with their effect on absorption potential of a compound or a compound product as well as approaches for evaluating in vivo relevant differences between formulations of a compound through their effect on the absorption potential of the compound.
1. A method for assessing an in vivo absorption of a compound or a compound product, the method comprising:
introducing the compound or the compound product into a first or a dissolution medium;
allowing dissolved compound or compound product to transfer from the first or the dissolution medium to a second or a receiving medium through a permeation membrane separating the first or the dissolution medium and the second or the receiving medium;
measuring the amount of dissolved compound or compound product in the second or the receiving medium as a function of time to determine an absorption potential parameter; and
(i) measuring the amount of dissolved compound or compound product in the first or the dissolution medium as a function of time to obtain a concentration profile or a dissolution rate;
monitoring for a change in the concentration profile or in the dissolution rate; and
comparing the change or a lack thereof in the concentration profile or the dissolution rate in the first or the dissolution medium with a change or lack thereof in the absorption potential parameter, or
(ii) measuring the amount of dissolved compound or compound product in the first or the dissolution medium as a function of time to obtain a concentration profile or a dissolution rate;
monitoring for a change in the absorption potential parameter; and
comparing the change or a lack thereof in the absorption potential parameter with a change or lack thereof in the concentration profile or the dissolution rate in the first or the dissolution medium,
wherein the second or the receiving medium is contained in a receiving vessel that is partially or completely immersed in the first or the dissolution medium.
2. The method of claim 1 , wherein the first or dissolution medium is contained in a dissolution vessel that includes a basket or a paddle.
3. The method of claim 2 , wherein the dissolution vessel has a volume of 250 mL, 500 mL or 900 mL.
4. The method of claim 1 , wherein the first or the dissolution medium is a model for an in vivo medium on a donor side of an in vivo membrane and/or the second or the receiving medium is a model for an in vivo medium on an acceptor side of the in vivo membrane.
5. The method of claim 1 , further comprising expressing the absorption potential parameter as a flux of the compound or compound product through the permeation membrane, wherein the flux is the amount of the compound or compound product penetrating through the membrane ver unit area ver unit time.
6. The method of claim 1 , further comprising stirring at least one of the first or the dissolution medium and the second or the receiving medium.
7. The method of claim 1 , wherein the compound or the compound product is provided as a loose powder, a compacted powder, a liquid formulation, a viscous formulation, a patch formulation or a sublingual strip formulation or wherein the compound is a pharmaceutically active ingredient, a veterinary, toxic or a hazardous substance, a dietary supplement, or a recreational drug.
8. The method of claim 1 , further comprising measuring the amount of dissolved compound or compound product in the first or the dissolution medium, the amount of dissolved compound or compound product in the second or the receiving medium or the amount of dissolved compound or compound product in both media by a spectroscopic or potentiometric technique in situ, or on a continuous basis, or by withdrawing aliquots.
9. The method of claim 1 , wherein the membrane is or mimics an in-vivo membrane.
10. The method of claim 1 , wherein the membrane is selected from the group consisting of a PAMPA type membrane-, a cell mono or multi-layer, a skin or skin-like membrane, a dialysis membrane, a mucosal membrane, an ocular membrane, and a corneal membrane.
11. The method of claim 1 , wherein the volume occupied by the second or the receiving medium is smaller than the volume occupied by the first or the dissolution medium, or wherein the first or the dissolution medium is a donor medium and the second medium is a receiving medium.
12. The method of claim 1 , further comprising comparing amounts of compound or compound product or dissolved compound or compound product determined as a function of time in the first or the dissolution medium, in the second or the receiving medium or both with calibration curves to determine the BCS class of the compound, or the method of claim 1 , further comprising computerized data collection and/or analysis.
13. A method for assessing effects of permeation on a dissolution rate of a compound, the method comprising:
introducing the compound into a dissolution medium;
allowing the compound to permeate through a semipermeable membrane to a receiving medium;
measuring a first concentration of the compound in the dissolution medium as a function of time to obtain a first concentration profile in the presence of permeation of the compound to the receiving medium; and
comparing the first concentration profile with a second concentration profile of the compound in the dissolution medium, wherein the second concentration profile is obtained in the absence of permeation to the receiving medium, to determine which parameter from the group consisting of dissolution rate, solubility and permeability is a limiting factor for absorption of the compound,
wherein the semipermeable membrane separates the dissolution medium and the receiving medium, and wherein the receiving medium is contained in a vessel that is partially or completely immersed in the dissolution medium.
14. The method of claim 13 , further comprising:
measuring amounts of the compound or dissolved compound as a function of time and in the presence of permeation in the dissolution medium, in the receiving medium or both; and
comparing the measured amounts of the compound or dissolved compound determined as a function of time in the dissolution medium, in the receiving medium or both, with calibration cures to determine the BCS class of the compound.
15. The method of claim 13 , wherein the semipermeable membrane is selected from the group consisting of a PAMPA type membrane, a cell mono or multi-layer, a skin or skin-like membrane, a dialysis membrane, a mucosal membrane, an ocular membrane and a corneal membrane.
16. The method of claim 13 , wherein the compound is provided as a loose powder, a compacted powder, a liquid formulation, a viscous formulation, a patch formulation or a sublingual strip formulation or wherein the compound is a pharmaceutically active ingredient, a veterinary, toxic or a hazardous substance, a dietary supplement, or a recreational drug.
17. The method of claim 13 , further comprising measuring the first concentration of the compound by a spectroscopic or potentiometric technique conducted in situ, or on a continuous basis, or by withdrawing aliquots.